EnnoDC

Executive Summary

EnnoDC is a clinical-stage French biotech founded in 2021, pioneering a novel class of immunotherapy known as Dendritic Cell (DC) engagers. Its proprietary antibodies simultaneously target CD40 on dendritic cells and deliver specific antigens, aiming to induce precise, broad, and durable immune responses. The company's pipeline targets both oncology and infectious diseases, with lead programs in HPV+ oropharyngeal cancer, prostate cancer, HIV, and COVID-19. EnnoDC's approach is designed to address the limitations of existing immunotherapies by leveraging dendritic cells' central role in activating adaptive immunity. As a private, Phase 1 company, EnnoDC represents a high-risk, high-reward opportunity in the immunotherapy space, with potential differentiation if its technology demonstrates safety and efficacy in early clinical trials. The company's innovative mechanism and diverse pipeline indicate strategic breadth, but the absence of disclosed funding and early-stage status necessitate caution.

Upcoming Catalysts (preview)

• Q1 2027Initial Phase 1 data readout for lead DC engager in HPV+ oropharyngeal cancer30% success
• Q4 2026IND filing or Phase 1 initiation for HIV program40% success
• Q3 2026Partnership or licensing deal for COVID-19 or infectious disease program50% success